Veeva Systems/$VEEV
1D1W1MYTD1Y5YMAX
Capital at risk
About Veeva Systems
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
- Ticker
- $VEEV
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 7,928
- Headquarters
- Pleasanton, United States
- Website
- www.veeva.com
Veeva Systems Metrics
BasicAdvanced
$46B
46.22
$6.10
0.97
-
Price and volume
Market cap
$46B
Beta
0.97
52-week high
$310.50
52-week low
$148.05
Average daily volume
1.8M
Financial strength
Current ratio
5.458
Quick ratio
5.363
Long term debt to equity
0.018
Total debt to equity
0.02
Profitability
EBITDA (TTM)
1,075.341
Gross margin (TTM)
74.96%
Net profit margin (TTM)
29.34%
Operating margin (TTM)
29.93%
Effective tax rate (TTM)
23.55%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
7.58%
Return on equity (TTM)
14.42%
Valuation
Price to earnings (TTM)
46.219
Price to revenue (TTM)
13.331
Price to book
6.14
Price to tangible book (TTM)
6.63
Price to free cash flow (TTM)
28.132
Free cash flow yield (TTM)
3.55%
Free cash flow per share (TTM)
10.022
Growth
Revenue change (TTM)
16.50%
Earnings per share change (TTM)
25.52%
3-year revenue growth (CAGR)
15.71%
10-year revenue growth (CAGR)
22.03%
3-year earnings per share growth (CAGR)
22.48%
10-year earnings per share growth (CAGR)
32.35%
What the Analysts think about Veeva Systems
Analyst ratings (Buy, Hold, Sell) for Veeva Systems stock.
Analyst projections of the future price of Veeva Systems stock.
Bulls say / Bears say
Veeva beat its second-quarter targets with revenue up 18% to $928.0 million and subscription revenue up 16%. It also raised full-year fiscal 2027 revenue guidance to $3.682–$3.687 billion and adjusted EPS guidance to about $9.21. (Veeva Systems)
Vault CRM adoption is gaining traction among large pharmaceutical customers. Veeva reported 190 live customers and commitments from 14 of the top 20 biopharmas, including a new global commitment from Amgen. (PR Newswire, Veeva Systems)
Veeva is expanding beyond core software with industry-specific AI agents and broader R&D and quality products. Falcon, Vault AI and new offerings such as Falcon MLR could increase productivity for customers and create additional revenue opportunities across Veeva’s installed base. (Veeva Systems, PR Newswire)
The growth rate is set to slow after the strong second quarter. The midpoint of Veeva’s third-quarter forecast implies roughly 15% growth, while the full-year outlook implies growth easing to about 12.5% by the January quarter as the CRM migration tailwind matures. (Veeva Systems, TIKR)
The latest growth mix raises questions about profit quality. Professional-services revenue grew faster than subscriptions, its non-GAAP gross margin fell to 31.5% from 33.4%, and quarterly operating cash flow was nearly flat year on year; further AI investment could add pressure. (Insider Monkey, Veeva Systems)
The shares leave limited room for disappointment, with Veeva trading at a premium earnings multiple while analysts still flag Salesforce and Oracle competition in CRM. AI monetisation and customer adoption are also early, so a slower rollout could expose the valuation. (Simply Wall St, Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
Veeva Systems Financial Performance
Revenues and expenses
Veeva Systems Earnings Performance
Company profitability
Upcoming events
No upcoming events
Veeva Systems News
AllArticlesVideos
Funds containing Veeva Systems
AllEURGBPUSD
Fund name | Fund size | $VEEV weighting |
|---|---|---|
VanEck Morningstar Wide Moat€GMVM | €407M | 3.57% |
VanEck Morningstar Wide Moat£MOGB | £354M | 3.57% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 1.11% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.70% |
Amundi S&P 500£500G | £6.6B | 0.67% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.